Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
36.76
-0.81 (-2.16%)
At close: Jul 19, 2024, 4:00 PM
36.77
+0.01 (0.03%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CLDX stock have an average target of 66, with a low estimate of 27 and a high estimate of 90. The average target predicts an increase of 79.54% from the current stock price of 36.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CLDX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +117.63% | Jul 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $67 | Buy | Reiterates | $67 | +82.26% | Jun 18, 2024 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +117.63% | Jun 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +117.63% | May 15, 2024 |
Financial Forecast
Revenue This Year
2.77M
from 6.88M
Decreased by -59.70%
Revenue Next Year
2.83M
from 2.77M
Increased by 2.05%
EPS This Year
-2.36
from -2.92
EPS Next Year
-3.01
from -2.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.5M | 5.7M | 5.3M | 125.0M | 764.2M |
| Avg | 2.8M | 2.8M | 2.3M | 60.2M | 413.6M |
| Low | n/a | n/a | n/a | n/a | 157.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -20.7% | 104.4% | 85.4% | 5,344.4% | 1,169.4% |
| Avg | -59.7% | 2.1% | -18.9% | 2,523.1% | 587.1% |
| Low | - | - | - | - | 160.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.99 | -2.80 | -2.80 | -3.84 | -1.92 |
| Avg | -2.36 | -3.01 | -3.69 | -3.73 | -1.87 |
| Low | -2.60 | -3.36 | -4.48 | -3.59 | -1.79 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.